Proud that the Alliance for Pulmonary Hypertension has been awarded a 2023 #RAREis Global Advocate Grant by Horizon Therapeutics!

We are proud to have been awarded a 2023 #RAREis Global Advocate Grant by Horizon Therapeutics#RAREis program, which recognizes contributions to advancing, educating and addressing the needs of the rare disease community. We look forward to continuing to make a meaningful difference for those affected by pulmonary hypertension!

The 2023 #RAREis Global Advocate Grant program was announced in February 2023 on the occasione of International Rare Disease Day. Horizon received nearly 190 applications, from 33 countries, representing more than 180 different rare diseases. The 50 organizations awarded the grant in 2023 represent 12 countries and focus on supporting 40 different rare diseases. Eight of the advocacy groups are recipients again this year, enabling continued programming from 2022.

Learn more about the #RAREis Global Advocate Grant and the other incredible organizations honored at this link

Horizon is a global biotechnology company focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. For more information visit and follow Twitter LinkedIn, Instagram and Facebook.

Scroll to Top